1Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6) [J]. GERCOR. Eur J Cancer, 1999,35(9):1338-1342.
2Trump DL, Egorin MJ, Forrest A, et al. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole [J]. J Clin Oncol, 1991,9(11) :2027-2035.
3Thyss A, Milano G, Renee N, et al. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer [J]. Cancer Chemother Pharmacol, 1986, 16 (1) :64-66.
4Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil[J]. Clin Pharmacokinet, 1989,16(4) :215-237.
5Gamelin E, Boisdron-Celle M, Larra F, et al. A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites [J]. J Liq Chrom & Rel Technol, 1997,20(19) :3155-3172.
6Gamelin E, Botsdron-Celle M, Tureant A, et al. Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma [J]. J Chronmatogr Biomed Sci,1997,695(2) :406-416.
7Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients[J]. J Clin Oncol, 1994, 12(11): 2248-2253.
8Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion [J].Cancer Res, 1990,50(1): 197-201.
9Keizer HJ, De Bruijn EA, Tjaden UR, et al. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine [J]. J Cancer Res Clin Oncol, 1994, 120(9) :545-549.
10Van Kuilenburg AB, De Abreu RA, van Gennip AH.Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency [J]. Ann Clin Biochem, 2003,40(Pt 1) :41-45.
